Bernstein Upgrades Biogen to Outperform, Announces $500 Price Target

Bernstein analyst Aaron Gal upgrades Biogen (NASDAQ:BIIB) from Market Perform to Outperform and announces $500 price target.

Bernstein analyst Aaron Gal upgrades Biogen (NASDAQ:BIIB) from Market Perform to Outperform and announces $500 price target.

Total
0
Shares
Related Posts